Drug-induced lupus erythematosus historical perspective

Jump to navigation Jump to search

Drug-induced lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Drug-induced lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Drug-induced lupus erythematosus historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Drug-induced lupus erythematosus historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Drug-induced lupus erythematosus historical perspective

CDC on Drug-induced lupus erythematosus historical perspective

Drug-induced lupus erythematosus historical perspective in the news

Blogs on Drug-induced lupus erythematosus historical perspective

Directions to Hospitals Treating Drug-induced lupus erythematosus

Risk calculators and risk factors for Drug-induced lupus erythematosus historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Hydralazine was the first agent to be associated with the development of lupus-like symptoms in 1954. Since then, more than 100 drugs have been identified as the cause of drug-induced lupus, with the list expanding with the development of newer biologic agents each year. https://www.ncbi.nlm.nih.gov/books/NBK441889/

References

Template:WikiDoc Sources